Key Producers of Anti-VEGF Therapeutics:
- Biogen Inc.
- F. Hoffmann-La Roche Ltd.
- Sandoz Group AG
- Bausch Health Companies Inc.
- Viatris Inc.
- Pfizer Inc.
- Amgen Inc.
- Regeneron Pharmaceuticals Inc.
- Bayer AG
- Novartis AG
- AbbVie Inc.
- Xbrane Biopharma AB
Anti-VEGF Therapeutics Market Share
Explore Comprehensive Insights into the Anti-VEGF Therapeutics Market Share from 2019 to 2030 Understand How Competitive Dynamics are Shifting.
Market Share for Anti-VEGF Therapeutics
The anti-vascular endothelial growth factor market is consolidated because only a handful of pharmaceutical companies have received a regulatory approval for these drugs. Being an extensively regulated industry, pharmaceuticals present high entry barriers for new companies. R&D, production, clinical trials, and regulatory approval require high capital investments, which only established drug makers are able to make. Additionally, drug patents are heavily protected and can last for 20 years, prohibiting non-patent holders from making the drug. This is why as the more existing patents expire and biosimilar versions of these medicines emerge, the market might move toward fragmentation in future.
